HASAKO S ET AL: "Characterization of antitumor activity of TAS6417, a novel EGFR-TKI targeting exon 20 insertions", MOLECULAR CANCER THERAPEUTICS; AACR-NCI-EORTC INTERNATIONAL CONFERENCE: MOLECULAR TARGETS AND CANCER THERAPEUTICS; OCTOBER 26-30, 2017; PHILADELPHIA, PA, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US , vol. 17, no. 1, Supplement 1 1 January 2018 (2018-01-01), page A158, XP009519607, ISSN: 1538-8514, DOI: 10.1158/1535-7163.TARG-17-A158 Retrieved from the Internet: URL:https://mct.aacrjournals.org/content/1 7/1_Supplement/A158 (B1)

HASAKO S ET AL: "TAS6417, a novel EGFR inhibitor targeting exon 20 insertion mutations", MOLECULAR CANCER THERAPEUTICS, AMERICAN ASSOCIATION FOR CANCER RESEARCH [, US, vol. 17, no. 8, 1 August 2018 (2018-08-01) , pages 1648-1658, XP009519606, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-17-1206 (B1)

YANG, JAMES C-H et al.: "Clinical activity of afatinib in patients with advanced non-small- cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6", Lancet Oncol., vol. 16, 2015, pages 830-838, XP055578862, ISSN: 1470-2045 (B1)

NISHINO, KAZUMI et al.: "Guidelines of examination about EGFR gene mutations in lung cancer patient", Guide for EGFR gene mutation testing in lung cancer patients , 1 December 2016 (2016-12-01), pages 1-35, XP009519528, Retrieved from the Internet: URL:https://www.haigan.gr.jp/uploads/files /photos/1329.pdf [retrieved on 2018-10-18] (B1)

WO-A1-2015/025936 (B1)

KOBAYASHI, YOSHIHISA et al.: "Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy", Cancer Science, vol. 107, no. 9, 2016, pages 1179-1186, XP055486102, ISSN: 1349-7006, DOI: 10.1111/cas.12996 (B1)